查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1363106

核酸藥物CDMO市場規模、佔有率、趨勢分析報告：按類型、服務、最終用戶、用途、地區和細分市場預測，2023-2030年

Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis Report By Type, By Service (Process Development & Optimization, Manufacturing Services), By End-user, By Application, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

核酸藥物CDMO市場成長及趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年，全球核酸藥物CDMO市場規模將達到224.2億美元，2023年至2030年年複合成長率為9.4%。

市場成長主要是由核酸藥物需求增加、核酸技術進步以及 FDA 對核酸藥物核准的增加等要素推動的，從而推動了對具有成本效益的合約開發和製造服務的需求。

生技公司、製藥公司和學術機構對基因治療研發的投資和興趣不斷增加，正在推動對 CDMO 服務的需求。 CDMO 在基因治療製造中發揮重要作用。例如，作為 Sarepta Therapeutics 的商業製造合作夥伴，Catalent 在推進基因治療解決方案方面發揮關鍵作用。

mRNA疫苗應對COVID-19大流行的成功展示了核酸醫學的潛力，並刺激了該領域的進一步研究和投資。例如，賽諾菲在 2022 年 3 月宣布，將在未來年度內投入 10.2 億美元（9.35 億歐元）在法國開發信使 RNA 疫苗。賽諾菲將在 2026 年之前進行這項投資，作為 2021 年 6 月宣布的 20 億歐元全球投資計畫的一部分。這項舉措旨在進一步推進公司的 mRNA 策略。這種增資情境將促進市場成長。

此外，不斷增加的 CDMO收購和合作預計將在未來年度加速核酸藥物 CDMO 市場的成長。例如，2022 年 5 月，eureKARE 進行了價值 1.6098 億美元（1.5 億歐元）的合併，創建了一個細胞和基因治療合約開發和製造組織 (CDMO)。

該公司成立了特殊目的收購公司 eureKING (SPAC)，以整合三個歐洲受託製造廠商(CDMO)。此外，FUJIFILM將於 2022 年 4 月透過收購加州 Atara Biotherapeutics, Inc. 的一家專門從事細胞治療的製造設施，擴大其作為先進療法合約開發和受託製造廠商(CDMO) 的產品組合。此類配合措施預計將促進市場成長。

核酸醫藥CDMO市場報告亮點

  • 2022 年，基於 RNA 的治療領域佔據了最大的收益佔有率。基於 RNA 的療法（主要是 mRNA）可用於治療多種疾病。它們可以被設計為產生多種治療性蛋白質，從而適用於不同的治療領域。
  • 預計基因治療領域的市場在未來年度將顯著成長。這是因為基因治療的臨床成功正在幫助擴大其適應症。
  • 2022年，製造服務領域佔據市場主導地位，佔總收益佔有率的38%以上。促進該領域成長的主要挑戰包括複雜的製造流程、規模化和生產挑戰以及成本效率。
  • 生技公司在2022年佔據領先的收益佔有率，超過58%，因為它們大力投資於創新治療方法的研發。
  • 從用途來看，腫瘤學在 2022 年以超過 31.0% 的收益佔有率引領全球市場。這是由於擴大採用基因療法和基於 RNA 的療法，以及用於腫瘤學的核酸藥物的管道不斷增加。
  • 2022年，北美在核酸治療CDMO市場中佔據最大收益佔有率，達到38.49%。大量的投資和資金、強大的學術和研究機構以及 CDMO 不斷擴大的全球影響力正在推動該地區的成長。

目錄

第1章 調查方法與範圍

第2章 執行摘要

第3章 市場變數、趨勢和範圍

  • 市場區隔和範圍
  • 市場體系預測
    • 母市場預測
    • 相關/附隨市場預測
  • 市場趨勢及展望
  • 市場動態
  • 市場促進因素分析
  • 市場抑制因素分析
  • 營商環境分析
    • SWOT分析
    • 波特五力分析
  • COVID-19感染疾病的影響分析

第4章 按類型分類的業務分析

  • 核酸藥物CDMO市場：類型變異分析
  • 基因治療
  • 基於RNA的治療

第5章 依服務分類的業務分析

  • 核酸醫藥CDMO市場：服務波動分析
  • 製程開發與最佳化
  • 製造服務
  • 分析和品管服務
  • 其他

第6章 最終使用者的業務分析

  • 核酸藥物CDMO市場：終端用戶波動分析
  • 製藥公司
  • 政府及學術研究機構
  • 生技公司

第7章 用途業務分析

  • 核酸藥物CDMO市場：用途變異分析
  • 腫瘤學
  • 遺傳疾病
  • 感染疾病
  • 其他

第8章 區域業務分析

  • 2022年及2030年按地區分類的核酸藥物CDMO市場佔有率
  • 北美洲
    • 2018-2030年北美核酸藥物CDMO市場
    • 美國
    • 加拿大
  • 歐洲
    • 2018-2030年歐洲核酸藥物CDMO市場
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麥
  • 亞太地區
    • 2018-2030年亞太核酸藥物CDMO市場
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 2018-2030年拉丁美洲核酸藥物CDMO市場
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東/非洲
    • MEA核酸醫藥CDMO市場，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭形勢

  • 公司分類
  • 策略規劃
    • 併購
    • 合作
    • 新產品發布
  • 參與企業概況
    • Catalent
    • Thermo Fisher Scientific
    • Lonza
    • FUJIFILM Diosynth Biotechnologies
    • Cognate BioServices
    • Eurofins Genomics
    • Sirion Biotech
    • Oxford Biomedica
    • Danaher（Aldevron）
Product Code: GVR-4-68040-125-4

Nucleic Acid Therapeutics CDMO Market Growth & Trends:

The global nucleic acid therapeutics CDMO market size is expected to reach USD 22.42 billion by 2030, advancing at a CAGR of 9.4% from 2023 to 2030, according to a new report by Grand View Research, Inc.. The market's growth is primarily attributed to factors such as increasing demand for nucleic acid therapeutics, advancements in nucleic acid technologies, and rising FDA approvals of nucleic acid therapeutics, propelling the need for cost-effective contract development and manufacturing services.

Growing investment and interest in gene therapy research and development by biotechnology companies, pharmaceutical firms, and academic institutions are driving the demand for CDMO services. CDMOs have played a crucial role in gene therapy manufacturing. For instance, Catalent has taken on the primary role as the commercial manufacturing partner for Sarepta Therapeutics in their efforts to advance gene therapy solutions.

The success of mRNA vaccines in responding to the COVID-19 pandemic has showcased the potential of nucleic acid therapeutics, stimulating further research and investment in this field. For instance, in March 2022, Sanofi announced that it plans to allocate USD 1.02 billion (935 million euros) for the development of messenger RNA vaccines in France over the coming years. Sanofi intends to allocate this investment until 2026 as a part of a 2-billion-euro global investment initiative unveiled in June 2021. This initiative is designed to expedite the company's mRNA strategy. Such increased funding scenarios drive market growth.

Furthermore, increasing incidences of CDMO acquisitions and partnerships are expected to accelerate the market growth for nucleic acid therapeutics CDMO in the coming years. For instance, in May 2022, eureKARE initiated a merger worth USD 160.98 million (€150 million) to create a cell & gene therapy contract development and manufacturing organization (CDMO).

The company has established eureKING, a Special Purpose Acquisition Company (SPAC), with the aim of merging three European Contract Development and Manufacturing Organizations (CDMOs) into a unified entity. In another instance, in April 2022, Fujifilm broadened its Advanced Therapies Contract Development and Manufacturing Organization (CDMO) portfolio by acquiring a specialized cell therapy manufacturing facility from Atara Biotherapeutics, Inc. located in California. Such initiatives are expected to boost market growth.

Nucleic Acid Therapeutics CDMO Market Report Highlights:

  • The RNA-based therapies segment held the largest revenue share in 2022. RNA-based therapies, mainly mRNA, offer versatility in addressing various diseases. They can be designed to produce a variety of therapeutic proteins, making them applicable to diverse therapeutic areas
  • The gene therapy segment is expected to show significant market growth in the coming years. This is attributed to the clinical success of gene therapies, which have helped in expanding indications of gene therapies
  • In 2022, the manufacturing services segment dominated the market, accounting for over 38% of the total revenue share. Key factors contributing to segment growth include complex manufacturing processes, scale-up & production challenges, and cost efficiency
  • The biotechnology companies held a major revenue share of over 58% in 2022 due to substantial investments in the research and development of innovative therapies
  • By application, the oncology segment led the global market with a revenue share of over 31.0% in 2022. This is attributed to the rising adoption of gene therapy and RNA-based therapeutics and the increasing pipeline of nucleic acid therapeutics for oncology
  • North America held the largest revenue share of 38.49% in the nucleic acid therapeutic CDMO market in 2022. Substantial investments and funding support, strong academic and research institutions, and global expansion of CDMOs drive regional growth

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Information Procurement
  • 1.2. Information or Data Analysis
  • 1.3. Market Scope & Segment Definition
  • 1.4. Market Model

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Segmentation and Scope
  • 3.2. Market Lineage Outlook
    • 3.2.1. Parent Market Outlook
    • 3.2.2. Related/Ancillary Market Outlook
  • 3.3. Market Trends and Outlook
  • 3.4. Market Dynamics
  • 3.5. Market Driver Analysis
  • 3.6. Market Restraint Analysis
  • 3.7. Business Environment Analysis
    • 3.7.1. SWOT Analysis
    • 3.7.2. Porter's Five Forces Analysis
  • 3.8. COVID-19 Impact Analysis

Chapter 4. Type Business Analysis

  • 4.1. Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
  • 4.2. Gene Therapy
    • 4.2.1. Gene Therapy Market, 2018 - 2030 (USD Billion)
  • 4.3. RNA-based Therapies
    • 4.3.1. RNA-based Therapies Market, 2018 - 2030 (USD Billion)

Chapter 5. Service Business Analysis

  • 5.1. Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
  • 5.2. Process Development and Optimization
    • 5.2.1. Process Development and Optimization Market, 2018 - 2030 (USD Billion)
  • 5.3. Manufacturing Services
    • 5.3.1. Manufacturing Services Market, 2018 - 2030 (USD Billion)
  • 5.4. Analytical and Quality Control Services
    • 5.4.1. Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
  • 5.5. Others
    • 5.5.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. End Users Business Analysis

  • 6.1. Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
  • 6.2. Pharmaceutical Companies
    • 6.2.1. Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • 6.3. Government & Academic Research Institutes
    • 6.3.1. Government & Academic Research Institutes Market, 2018 - 2030 (USD Billion)
  • 6.4. Biotech Companies
    • 6.4.1. Biotech Companies Market, 2018 - 2030 (USD Billion)

Chapter 7. Application Business Analysis

  • 7.1. Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
  • 7.2. Oncology
    • 7.2.1. Oncology Market, 2018 - 2030 (USD Billion)
  • 7.3. Genetic Disorders
    • 7.3.1. Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • 7.4. Infectious Diseases
    • 7.4.1. Infectious Diseases Market, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 8. Regional Business Analysis

  • 8.1. Nucleic Acid Therapeutics CDMO Market Share by Region, 2022 & 2030
  • 8.2. North America
    • 8.2.1. North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.2.2. U.S.
      • 8.2.2.1. Key Country Dynamics
      • 8.2.2.2. Regulatory Framework
      • 8.2.2.3. Competitive Scenario
      • 8.2.2.4. U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.2.3. Canada
      • 8.2.3.1. Key Country Dynamics
      • 8.2.3.2. Regulatory Framework
      • 8.2.3.3. Competitive Scenario
      • 8.2.3.4. Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.3. Europe
    • 8.3.1. Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.2. UK
      • 8.3.2.1. Key Country Dynamics
      • 8.3.2.2. Competitive Scenario
      • 8.3.2.3. UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.3. Germany
      • 8.3.3.1. Key Country Dynamics
      • 8.3.3.2. Competitive Scenario
      • 8.3.3.3. Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.4. France
      • 8.3.4.1. Key Country Dynamics
      • 8.3.4.2. Competitive Scenario
      • 8.3.4.3. France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.5. Italy
      • 8.3.5.1. Key Country Dynamics
      • 8.3.5.2. Competitive Scenario
      • 8.3.5.3. Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.6. Spain
      • 8.3.6.1. Key Country Dynamics
      • 8.3.6.2. Competitive Scenario
      • 8.3.6.3. Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.7. Sweden
      • 8.3.7.1. Key Country Dynamics
      • 8.3.7.2. Competitive Scenario
      • 8.3.7.3. Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.8. Norway
      • 8.3.8.1. Key Country Dynamics
      • 8.3.8.2. Competitive Scenario
      • 8.3.8.3. Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.3.9. Denmark
      • 8.3.9.1. Key Country Dynamics
      • 8.3.9.2. Competitive Scenario
      • 8.3.9.3. Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.4. Asia Pacific
    • 8.4.1. Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.2. Japan
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Competitive Scenario
      • 8.4.2.3. Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.3. China
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Competitive Scenario
      • 8.4.3.3. China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.4. India
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Competitive Scenario
      • 8.4.4.3. India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.5. Australia
      • 8.4.5.1. Key Country Dynamics
      • 8.4.5.2. Competitive Scenario
      • 8.4.5.3. Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.6. South Korea
      • 8.4.6.1. Key Country Dynamics
      • 8.4.6.2. Competitive Scenario
      • 8.4.6.3. South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.4.7. Thailand
      • 8.4.7.1. Key Country Dynamics
      • 8.4.7.2. Competitive Scenario
      • 8.4.7.3. Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.5. Latin America
    • 8.5.1. Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.2. Brazil
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Competitive Scenario
      • 8.5.2.3. Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.3. Mexico
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Competitive Scenario
      • 8.5.3.3. Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.5.4. Argentina
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Competitive Scenario
      • 8.5.4.3. Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • 8.6. MEA
    • 8.6.1. MEA Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.2. South Africa
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Competitive Scenario
      • 8.6.2.3. South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.3. Saudi Arabia
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Competitive Scenario
      • 8.6.3.3. Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.4. UAE
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Competitive Scenario
      • 8.6.4.3. UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
    • 8.6.5. Kuwait
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Competitive Scenario
      • 8.6.5.3. Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization
  • 9.2. Strategy Mapping
    • 9.2.1. Mergers & Acquisitions
    • 9.2.2. Collaborations
    • 9.2.3. New Product Launches
  • 9.3. Participant's overview
    • 9.3.1. Catalent
      • 9.3.1.1. Overview
      • 9.3.1.2. Financial Performance
      • 9.3.1.3. Product Benchmarking
      • 9.3.1.4. Strategic Initiatives
    • 9.3.2. Thermo Fisher Scientific
      • 9.3.2.1. Overview
      • 9.3.2.2. Financial Performance
      • 9.3.2.3. Product Benchmarking
      • 9.3.2.4. Strategic Initiatives
    • 9.3.3. Lonza
      • 9.3.3.1. Overview
      • 9.3.3.2. Financial Performance
      • 9.3.3.3. Product Benchmarking
      • 9.3.3.4. Strategic Initiatives
    • 9.3.4. FUJIFILM Diosynth Biotechnologies
      • 9.3.4.1. Overview
      • 9.3.4.2. Financial Performance
      • 9.3.4.3. Product Benchmarking
      • 9.3.4.4. Strategic Initiatives
    • 9.3.5. Cognate BioServices
      • 9.3.5.1. Overview
      • 9.3.5.2. Financial Performance
      • 9.3.5.3. Product Benchmarking
      • 9.3.5.4. Strategic Initiatives
    • 9.3.6. Eurofins Genomics
      • 9.3.6.1. Overview
      • 9.3.6.2. Financial Performance
      • 9.3.6.3. Product Benchmarking
      • 9.3.6.4. Strategic Initiatives
    • 9.3.7. Sirion Biotech
      • 9.3.7.1. Overview
      • 9.3.7.2. Financial Performance
      • 9.3.7.3. Product Benchmarking
      • 9.3.7.4. Strategic Initiatives
    • 9.3.8. Oxford Biomedica
      • 9.3.8.1. Overview
      • 9.3.8.2. Financial Performance
      • 9.3.8.3. Product Benchmarking
      • 9.3.8.4. Strategic Initiatives
    • 9.3.9. Danaher (Aldevron)
      • 9.3.9.1. Overview
      • 9.3.9.2. Financial Performance
      • 9.3.9.3. Product Benchmarking
      • 9.3.9.4. Strategic Initiatives

List of Tables

  • Table 1 List of data sources
  • Table 2 Global Nucleic Acid Therapeutics CDMO Market, by region, 2018 - 2030 (USD Billion)
  • Table 3 Global Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 4 Global Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 5 Global Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 6 Global Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 7 North America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 8 North America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 9 North America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 10 North America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 11 North America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 12 U.S. Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 13 U.S. Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 14 U.S. Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 15 U.S. Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 16 Canada Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 17 Canada Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 18 Canada Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 19 Canada Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 20 Europe Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 21 Europe Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 22 Europe Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 23 Europe Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 24 Europe Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 25 UK Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 26 UK Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 27 UK Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 28 UK Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 29 Germany Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 30 Germany Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 31 Germany Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 32 Germany Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 33 France Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 34 France Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 35 France Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 36 France Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 37 Italy Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Italy Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 39 Italy Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 40 Italy Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 41 Spain Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 42 Spain Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 43 Spain Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 44 Sapin Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 45 Denmark Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 46 Denmark Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 47 Denmark Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 48 Denmark Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 49 Sweden Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 50 Sweden Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 51 Sweden Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 52 Sweden Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 53 Norway Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Norway Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 55 Norway Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 56 Norway Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 57 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 58 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 59 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 60 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 61 Asia Pacific Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 62 Japan Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 63 Japan Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 64 Japan Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 65 Japan Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 66 China Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 67 China Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 68 China Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 69 China Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 70 India Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 71 India Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 72 India Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 73 India Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 74 South Korea Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 75 South Korea Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 76 South Korea Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 77 South Korea Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 78 Australia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 79 Australia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 80 Australia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 81 Australia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 82 Thailand Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Thailand Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 84 Thailand Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 85 Thailand Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 86 Latin America Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 87 Latin America Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 88 Latin America Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 89 Latin America Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 90 Latin America Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 91 Brazil Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 92 Brazil Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 93 Brazil Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 94 Brazil Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 95 Mexico Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 96 Mexico Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 97 Mexico Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 98 Mexico Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 99 Argentina Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 100 Argentina Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 101 Argentina Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 102 Argentina Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 103 MEA Nucleic Acid Therapeutics CDMO Market, by country, 2018 - 2030 (USD Billion)
  • Table 104 MEA Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 105 MEA Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 106 MEA Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 107 MEA Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 108 South Africa Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 109 South Africa Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 110 South Africa Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 111 South Africa Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 112 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 113 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 114 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 115 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 116 UAE Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 117 UAE Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 118 UAE Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 119 UAE Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 120 Kuwait Nucleic Acid Therapeutics CDMO Market, by type, 2018 - 2030 (USD Billion)
  • Table 121 Kuwait Nucleic Acid Therapeutics CDMO Market, by service, 2018 - 2030 (USD Billion)
  • Table 122 Kuwait Nucleic Acid Therapeutics CDMO Market, by End Users, 2018 - 2030 (USD Billion)
  • Table 123 Kuwait Nucleic Acid Therapeutics CDMO Market, by Application, 2018 - 2030 (USD Billion)
  • Table 124 Participant's overview
  • Table 125 Financial performance
  • Table 126 Type benchmarking
  • Table 127 Strategic Initiatives

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Market research approaches
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment.
  • Fig. 7 Market formulation & validation
  • Fig. 8 Nucleic Acid Therapeutics CDMO Market revenue, 2018-2030 (USD Billion)
  • Fig. 9 Nucleic Acid Therapeutics CDMO Market Snapshot
  • Fig. 10 Nucleic Acid Therapeutics CDMO Market driver impact
  • Fig. 11 Nucleic Acid Therapeutics CDMO Market Restraint Impact
  • Fig. 12 Porter's 5 Forces Analysis
  • Fig. 13 PESTEL Analysis
  • Fig. 14 Global Nucleic Acid Therapeutics CDMO Market: Type Movement Analysis
  • Fig. 15 Global Nucleic Acid Therapeutics CDMO Market: Type Key Takeaways
  • Fig. 16 Global Gene Therapy Market, 2018 - 2030 (USD Billion)
  • Fig. 17 Global RNA-based Therapies Market, 2018 - 2030 (USD Billion)
  • Fig. 18 Global Nucleic Acid Therapeutics CDMO Market: Service Movement Analysis
  • Fig. 19 Global Nucleic Acid Therapeutics CDMO Market: Service Key Takeaways
  • Fig. 20 Global Process Development and Optimization Market, 2018 - 2030 (USD Billion)
  • Fig. 21 Global Manufacturing Services Market, 2018 - 2030 (USD Billion)
  • Fig. 22 Global Analytical and Quality Control Services Market, 2018 - 2030 (USD Billion)
  • Fig. 23 Global Others Market, 2018 - 2030 (USD Billion)
  • Fig. 24 Global Nucleic Acid Therapeutics CDMO Market: End Users Movement Analysis
  • Fig. 25 Global Nucleic Acid Therapeutics CDMO Market: End Users Key Takeaways
  • Fig. 26 Pharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • Fig. 27 Government & Academic Research Institute Market, 2018 - 2030 (USD Billion)
  • Fig. 28 Biotech Companies Market, 2018 - 2030 (USD Billion)
  • Fig. 29 Global Nucleic Acid Therapeutics CDMO Market: Application Movement Analysis
  • Fig. 30 Global Nucleic Acid Therapeutics CDMO Market: Application Key Takeaways
  • Fig. 31 Oncology Market, 2018 - 2030 (USD Billion)
  • Fig. 32 Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • Fig. 33 Infectious Diseases Market, 2018 - 2030 (USD Billion)
  • Fig. 34 Others Market, 2018 - 2030 (USD Billion)
  • Fig. 35 Regional Marketplace: Key Takeaways
  • Fig. 36 Regional Outlook, 2022 & 2030
  • Fig. 37 North America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 38 U.S. Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 39 Canada Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 40 Europe Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 41 Germany Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 42 UK Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 43 France Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 44 Italy Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 45 Spain Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 46 Denmark Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 47 Norway Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 48 Sweden Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 49 Asia Pacific Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 50 Japan Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 51 China Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 52 India Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 53 Australia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 54 South Korea Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 55 Thailand Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 56 Latin America Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 57 Brazil Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 58 Mexico Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 59 Argentina Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 60 Middle East and Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 61 South Africa Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 62 Saudi Arabia Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 63 UAE Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 64 Kuwait Nucleic Acid Therapeutics CDMO Market, 2018 - 2030 (USD Billion)
  • Fig. 65 Market participant categorization
  • Fig. 66 Heat map analysis